Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats
- PMID: 14963467
- DOI: 10.1038/sj.ijir.3901054
Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats
Abstract
Erectile dysfunction associated with diabetes mellitus is caused in part by disordered endothelial smooth muscle relaxation, neuropathy, and a decrease in cavernosal nitric oxide synthase (NOS) activity. The purpose of this study was to determine whether a combination of sildenafil and adenoviral gene transfer of endothelial NOS (eNOS) could enhance the erectile response in diabetic rats. Five groups of animals were utilized: (1) age-matched control rats, (2) streptozotocin (STZ)-induced diabetic rats (60 mg/kg i.p.), (3) STZ-rats + sildenafil (2 mg/kg i.v.), (4) STZ-rats transfected with AdCMVbetagal or AdCMVeNOS, and (5) STZ-rats transfected with AdCMVeNOS +sildenafil (2 mg/kg i.v.). At 2 months after i.p. injection of STZ, groups 4 and 5 were transfected with the adenoviruses and 1-2 days after transfection, all animals underwent cavernosal nerve stimulation (CNS) to assess erectile function. Cyclic 3',5'-guanosine monophosphate (cGMP) levels were assessed in the cavernosal tissue. STZ-diabetic rats had a significant decrease in erectile function as determined by the peak intracavernosal pressure (ICP) and total ICP (area under the erectile curve; AUC) after CNS when compared to control rats. STZ-diabetic rats+AdCMVeNOS had a peak ICP and AUC, which were similar to control animals. STZ-diabetic rats administered sildenafil demonstrated a significant increase in peak ICP at the 5 and 7.5 V settings, while the AUC was significantly increased at all voltage (V) settings. The increase in both ICP and AUC of STZ-diabetic rats transfected with AdCMVeNOS at all V settings was greater than STZ-diabetic rats transfected with AdCMVbetagal. STZ-diabetic rats transfected with AdCMVeNOS and administered sildenafil had a significant increase in total ICP that was greater than eNOS gene therapy alone. Cavernosal cGMP levels were significantly decreased in STZ-diabetic rats, but were increased after transfection with AdCMVeNOS to values greater than control animals. In conclusion, overexpression of eNOS and cGMP in combination with sildenafil significantly increased both the peak ICP and total ICP to CNS in the STZ-diabetic rat, which was similar to the response observed in control rats. Moreover, the total erectile response was greater in STZ-diabetic rats receiving eNOS gene therapy plus sildenafil than STZ-rats receiving sildenafil or eNOS gene therapy alone.
Similar articles
-
Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats.Int J Impot Res. 2012 May-Jun;24(3):114-21. doi: 10.1038/ijir.2011.54. Epub 2011 Dec 29. Int J Impot Res. 2012. PMID: 22205245
-
Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil.BJU Int. 2010 Jul;106(1):78-83. doi: 10.1111/j.1464-410X.2009.09104.x. Epub 2009 Dec 11. BJU Int. 2010. PMID: 20002674
-
Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats.J Urol. 2003 May;169(5):1911-7. doi: 10.1097/01.ju.0000051881.14239.4a. J Urol. 2003. PMID: 12686872
-
[Whole rehabilitation: a new goal of erectile dysfunction therapy].Zhonghua Nan Ke Xue. 2006 Sep;12(9):832-5. Zhonghua Nan Ke Xue. 2006. PMID: 17009539 Review. Chinese.
-
Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.Int J Impot Res. 2004 Dec;16(6):459-69. doi: 10.1038/sj.ijir.3901256. Int J Impot Res. 2004. PMID: 15229623 Review.
Cited by
-
Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction.Curr Urol Rep. 2011 Dec;12(6):432-43. doi: 10.1007/s11934-011-0216-y. Curr Urol Rep. 2011. PMID: 21922167 Review.
-
Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction.Br J Pharmacol. 2013 May;169(2):449-61. doi: 10.1111/bph.12143. Br J Pharmacol. 2013. PMID: 23441682 Free PMC article.
-
Mesenchymal stem cell-based gene therapy for erectile dysfunction.Int J Impot Res. 2016 May;28(3):81-7. doi: 10.1038/ijir.2016.3. Epub 2016 Feb 18. Int J Impot Res. 2016. PMID: 26888355 Review.
-
Current status of penile rehabilitation after radical prostatectomy.Korean J Urol. 2015 Feb;56(2):99-108. doi: 10.4111/kju.2015.56.2.99. Epub 2015 Jan 30. Korean J Urol. 2015. PMID: 25685296 Free PMC article. Review.
-
Emerging gene and stem cell therapies for the treatment of erectile dysfunction.Nat Rev Urol. 2010 Mar;7(3):143-52. doi: 10.1038/nrurol.2010.8. Epub 2010 Feb 16. Nat Rev Urol. 2010. PMID: 20157303 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical